pcn poster

Posters

Misdiagnoses and Comorbidities Among Participants in the Nexus Narcolepsy Registry

Background: Narcolepsy diagnosis can be challenging. Presence of comorbidities and overlapping symptoms between narcolepsy and other conditions may contribute to diagnostic delay and misd...

David Pasta , MS;

Danielle Hyman , PhD;

Kathleen Villa , MS;

Jed Black , MD;

Maurice Ohayon , MD, DSc, PhD;

Michael Thorpy , MD, CHBC;

Michael Williams , PhD;

03/01/2019

Post Hoc Analyses of the Effects of Baseline Sleep Quality on SHP465 Mixed Amphetamine Salts Extended-Release Treatment Response in Adults With ADHD

Background: Sleep problems are common in adults with attention-deficit/hyperactivity disorder (ADHD). This study examined the effect of baseline sleep quality on response to treatment wit...

03/01/2019

Predictors of Response and Remission in Patients With Treatment-Resistant Depression Treated With Esketamine

Objective: Identify patient and disease characteristics associated with greater likelihood of achieving response and remission with esketamine nasal spray (ESK) plus a newly initiated ora...

Ibrahim Turkoz , PhD;

Ella Daly , MB, BCh, BAO;

Jaskaran Singh , MD;

David Williamson , PhD, MBA;

Jack Sheehan , PhD, MBA, RPh;

Kristy Tardieu , BSN, MBA;

03/01/2019

Quality of Life, Functional Evaluation, and Work Productivity in Patients With Narcolepsy: Results From a Phase 3 Study of Solriamfetol (JZP-110)

INTRODUCTION: Solriamfetol, a selective dopamine/norepinephrine reuptake inhibitor, significantly decreased excessive sleepiness in a randomized, double-blind, placebo-controlled study of...

Michael Thorpy , MD, CHBC;

Giuseppe Plazzi , MD;

Yves Dauvilliers , MD, PhD;

Colin Shapiro , PhD, FRCPC, MBBCh;

Jed Black , MD;

Geert Mayer , MD;

Helene Emsellem , MD;

Dandan Chen , MD, PhD;

Robert Ryan , MS;

Gert Jan Lammers , PhD, MD;

Chevy Chase , MD;

Lawrence Carter , PhD;

03/01/2019

Randomized, Double-Blind Study of Fixed-Dose Esketamine Nasal Spray Plus Oral Antidepressant vs. Active Control in Treatment-Resistant Depression

Aim: Compare efficacy and safety of fixed doses of esketamine nasal spray plus oral antidepressant (AD) to oral AD plus placebo nasal spray for treatment-resistant depression (TRD). Met...

Dawn Vitagliano , BA;

Michael Liebowitz , MD;

Arun Ravindran , MB, PhD, MSc;

Raphael Gaillard , MD, PhD;

Hans van den Ameele , MD;

Maurizio Fava , MD, PhD;

Ella Daly , MB, BCh, BAO;

Madhukar Trivedi , MD;

Wayne Drevets , MD;

Jaskaran Singh , MD;

Rosanne Lane , MD, MSc, MS;

Maggie Fedgchin , PharmD;

Pilar Lim , MD, PhD;

Pierre Blier , MD, PhD;

David Hough , MD;

Rama Melkote , MSc, MPH;

Husseini Manji , MD;

03/01/2019

Rapid Sertraline Titration in the Treatment of Behavioral Disturbances Associated With VCI type Dementia - Case Study

Major Neurocognitive disorders with behavioral disturbance are commonly referred for psychiatric consultation. The use of anti-psychotics as a treatment modality in this population is hig...

03/01/2019

Rationale and Design of Four Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Extended-Release Viloxazine (SPN-812) for Pediatric ADHD

Background: Although stimulants are commonly used for attention-deficit/hyperactivity disorder (ADHD), 10–30% of patients have an inadequate response, adverse events, or comorbidities pre...

03/01/2019

Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features: Results of a 12-week Open-label Extension Study

Objective: To evaluate the efficacy and tolerability of longer-term treatment with lurasidone in patients with major depressive disorder (MDD) with mixed features.

Antony Loebel , MD;

Andrei Pikalov , MD, PhD;

Michael Tocco , PhD;

Stephen Stahl , MD;

Yongcai Mao , PhD;

03/01/2019

Lumateperone (ITI-007) for the Treatment of Schizophrenia: Overview of Placebo-Controlled Clinical Trials and an Open-label Safety Switching Study

Background: Lumateperone is a first-in-class agent in development for schizophrenia that acts synergistically through serotonergic, dopaminergic and glutamatergic systems.

Kimberly Vanover , PhD;

Jelena Saillard , MS, MBA;

Steven Glass , MD;

Susan Kazaouer , MD;

Michal Weingart , PhD;

Robert Davis , PhD;

Andrew Satlin , MD;

Sharon Mates , PhD;

03/01/2019

Long-Term Treatment With Adjunctive Buprenorphine/Samidorphan Combination in Patients With Major Depressive Disorder: Interim Phase 3 Study Results

Introduction: Buprenorphine/samidorphan (BUP/SAM) is an investigational opioid system modulator demonstrating efficacy versus placebo as an adjunctive treatment for major depressive disor...

Sanjeev Pathak , MD;

Arielle Stanford , MD;

Maurizio Fava , MD, PhD;

Asli Memisoglu , ScD;

Madhukar Trivedi , MD;

William Martin , PhD;

Michael Thase , MD;

J. Alexander Bodkin , MD;

Amy Claxton , PhD;

03/01/2019

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Rapid Refresh

Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics

04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and...

04/11/2024

Psych Congress NP Institute

Rapid Refresh

Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder

04/10/2024

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC,...

04/10/2024

Psych Congress NP Institute

Clinical Pearls

Tolerability Testing in Long-Acting Injectable Prescriptions

04/03/2024

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Posters

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Sign Up

Specialties

Events

Year Round Education

HMP Global Products